The goals of Core A are to provide cellular and molecular assays in support of all projects. The technologies and methods employed include flow and image cytometry;genetic analyses, cell and tissue culture support and development of common reagents. This Core and its personnel have had a long and productive history of application of specialized cell and molecular assays to the study of Werner Syndrome. These notably include flow and image cytometric assays of cell cycle, survival, DNA damage and telomere status, reagents and assays for Immunologic probes and gene silencing, as well as cell culture support for the broad variety of in vitro assays that is encompassed by this work. Both the characterization of WRN RecQ protein activities and the consequences of these activities on cellular phenotypes thus rely on the use of cell and molecular assays that are used in com man by all of the Projects within this P01 renewal application. The implementation, enhancement and where needed, development of these assays is a service will be most effectively and efficiently performed by this specialized Core in order to optimize their use by the P01 Projects.
Both the characterization of WRN RecQ protein activities and the consequences of these activities on cellular phenotypes rely on the use of Core A cell and molecular assays that are used in common by all of the Projects within this Program Project.
|Knijnenburg, Theo A; Wang, Linghua; Zimmermann, Michael T et al. (2018) Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Rep 23:239-254.e6|
|Orozco, Javier I J; Knijnenburg, Theo A; Manughian-Peter, Ayla O et al. (2018) Epigenetic profiling for the molecular classification of metastatic brain tumors. Nat Commun 9:4627|
|Schmitt, Michael W; Pritchard, Justin R; Leighow, Scott M et al. (2018) Single-Molecule Sequencing Reveals Patterns of Preexisting Drug Resistance That Suggest Treatment Strategies in Philadelphia-Positive Leukemias. Clin Cancer Res 24:5321-5334|
|Mikheev, Andrei M; Mikheeva, Svetlana A; Severs, Liza J et al. (2018) Targeting TWIST1 through loss of function inhibits tumorigenicity of human glioblastoma. Mol Oncol 12:1188-1202|
|Lee, Su-In; Celik, Safiye; Logsdon, Benjamin A et al. (2018) A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun 9:42|
|Salk, Jesse J; Schmitt, Michael W; Loeb, Lawrence A (2018) Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations. Nat Rev Genet 19:269-285|
|Davis, Luther; Zhang, Yinbo; Maizels, Nancy (2018) Assaying Repair at DNA Nicks. Methods Enzymol 601:71-89|
|Yu, Ming; Heinzerling, Tai J; Grady, William M (2018) DNA Methylation Analysis Using Droplet Digital PCR. Methods Mol Biol 1768:363-383|
|Kamath-Loeb, Ashwini S; Zavala-van Rankin, Diego G; Flores-Morales, Jeny et al. (2017) Homozygosity for the WRN Helicase-Inactivating Variant, R834C, does not confer a Werner syndrome clinical phenotype. Sci Rep 7:44081|
|Oshima, Junko; Sidorova, Julia M; Monnat Jr, Raymond J (2017) Werner syndrome: Clinical features, pathogenesis and potential therapeutic interventions. Ageing Res Rev 33:105-114|
Showing the most recent 10 out of 137 publications